Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

Activating ALK mutations are present in almost 10% of primary neuroblastomas and mark patients for treatment with small-molecule ALK inhibitors in clinical trials. However, recent studies have shown that multiple mechanisms drive resistance to these molecular therapies. We anticipated that detailed...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Cancer Research 2015-07, Vol.21 (14), p.3327-39
Hauptverfasser: Lambertz, Irina, Kumps, Candy, Claeys, Shana, Lindner, Sven, Beckers, Anneleen, Janssens, Els, Carter, Daniel R, Cazes, Alex, Cheung, Belamy B, De Mariano, Marilena, De Bondt, An, De Brouwer, Sara, Delattre, Olivier, Gibbons, Jay, Janoueix-Lerosey, Isabelle, Laureys, Geneviève, Liang, Chris, Marchall, Glenn M, Porcu, Michael, Takita, Junko, Trujillo, David Camacho, Van Den Wyngaert, Ilse, Van Roy, Nadine, Van Goethem, Alan, Van Maerken, Tom, Zabrocki, Piotr, Cools, Jan, Schulte, Johannes H, Vialard, Jorge, Speleman, Frank, De Preter, Katleen
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Activating ALK mutations are present in almost 10% of primary neuroblastomas and mark patients for treatment with small-molecule ALK inhibitors in clinical trials. However, recent studies have shown that multiple mechanisms drive resistance to these molecular therapies. We anticipated that detailed mapping of the oncogenic ALK-driven signaling in neuroblastoma can aid to identify potential fragile nodes as additional targets for combination therapies.
ISSN:1078-0432